Singapore, December 20, 2024 – ChemT Biotechnology is working closely with Cytiva, a global leader in bioprocessing and cell therapy technologies, to support innovation and progress in cell therapy manufacturing. The collaboration focuses on integrating ChemT Bio’s flagship product, Chemplify™, into key stages of T cell production.

Powered by ChemT Bio’s proprietary AI discovery platform, Chemplify™ is a novel small molecule designed to boost T cell expansion, addressing a longstanding challenge in scalable cell therapy manufacturing. Cytiva’s engagement highlights a shared commitment to advancing efficient, high-quality solutions for next-generation therapies.

This joint effort reflects a broader industry trend toward digitalization and automation in biologics and cell therapy workflows. By combining deep technology capabilities and domain expertise, the collaboration aims to improve manufacturing efficiency and expand patient access to life-saving cell-based treatments.